XBRANE BIOPHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.202 SEK | -2.88% |
|
-11.98% | -97.98% |
| May. 16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 | |
| May. 16 | Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 533.4 | 1,661 | 2,624 | 2,258 | 297.3 | 309 | - | - |
| Enterprise Value (EV) 1 | 378.6 | 1,421 | 2,329 | 2,064 | 450 | 391 | 424.7 | -18.49 |
| P/E ratio | -2.33 x | -5.99 x | -13.5 x | -12.2 x | -0.74 x | -1.5 x | 4.22 x | 0.88 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 169 x | 39.2 x | 1.25 x | 0.9 x | 0.45 x | 0.28 x |
| EV / Revenue | - | - | 150 x | 35.8 x | 1.89 x | 1.14 x | 0.62 x | -0.02 x |
| EV / EBITDA | -2.69 x | -6.5 x | -13.8 x | -13.8 x | -1.56 x | -2.36 x | 2.92 x | -0.04 x |
| EV / FCF | -2.53 x | -5.87 x | - | -8.51 x | -1.06 x | -9.09 x | 1.33 x | - |
| FCF Yield | -39.6% | -17% | - | -11.7% | -94.1% | -11% | 75.3% | - |
| Price to Book | - | 6.44 x | 6.08 x | 5.31 x | 1.74 x | 1.2 x | 0.76 x | 0.32 x |
| Nbr of stocks (in thousands) | 15,415 | 22,200 | 25,040 | 27,506 | 29,731 | 1,529,483 | - | - |
| Reference price 2 | 34.60 | 74.80 | 104.8 | 82.10 | 10.00 | 0.2020 | 0.2020 | 0.2020 |
| Announcement Date | 2/28/20 | 2/26/21 | 2/24/22 | 2/17/23 | 2/26/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 15.56 | 57.62 | 238.7 | 343.6 | 680.3 | 1,122 |
| EBITDA 1 | -140.5 | -218.7 | -168.4 | -149.6 | -288.4 | -165.5 | 145.5 | 511.5 |
| EBIT 1 | -164.6 | -225.3 | -180.6 | -166.2 | -322.2 | -182.9 | 126 | 489.8 |
| Operating Margin | - | - | -1,160.78% | -288.48% | -134.95% | -53.24% | 18.52% | 43.67% |
| Earnings before Tax (EBT) 1 | -166 | -226 | -183.2 | -168.5 | -322 | -186.2 | 126.5 | 811.6 |
| Net income 1 | -166 | -226 | -188.4 | -172.5 | -388.2 | -186.2 | 104.1 | 644.4 |
| Net margin | - | - | -1,210.88% | -299.41% | -162.6% | -54.19% | 15.31% | 57.45% |
| EPS 2 | -14.84 | -12.48 | -7.770 | -6.750 | -13.52 | -0.1350 | 0.0479 | 0.2292 |
| Free Cash Flow 1 | -149.8 | -242.3 | - | -242.4 | -423.4 | -43 | 320 | - |
| FCF margin | - | - | - | -420.75% | -177.38% | -12.51% | 47.04% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 219.93% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | 307.32% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/26/21 | 2/24/22 | 2/17/23 | 2/26/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.466 | 7.19 | 15.63 | 13.94 | 17.31 | 61.83 | 51.12 | 58.89 | 66.89 | 14.07 | 110.3 | 74.98 | 90.05 |
| EBITDA 1 | -28.25 | -32.9 | -28.37 | -37.64 | -50.74 | - | - | -81.6 | -69.24 | -76.04 | -18.5 | -49.5 | -46.5 |
| EBIT 1 | -32.14 | -36.78 | -32.4 | -41.99 | -55.04 | - | -88.65 | -89.72 | -86.53 | -85.14 | -22.34 | -54.04 | -50.89 |
| Operating Margin | -719.68% | -511.57% | -207.29% | -301.34% | -317.92% | - | -173.42% | -152.35% | -129.35% | -605.15% | -20.25% | -72.08% | -56.51% |
| Earnings before Tax (EBT) 1 | -32.93 | -37.51 | -33.05 | -42.61 | -55.33 | -57.86 | -90.58 | -80.95 | -92.64 | -97.11 | -67.56 | -66.95 | -66.65 |
| Net income 1 | -32.47 | -36.12 | -33.78 | -41.88 | -60.73 | -58.4 | -91.01 | -81.23 | -157.5 | -97.4 | -67.56 | -66.95 | -66.65 |
| Net margin | -727.07% | -502.39% | -216.08% | -300.57% | -350.79% | -94.45% | -178.05% | -137.94% | -235.5% | -692.34% | -61.24% | -89.3% | -74.02% |
| EPS 2 | -1.320 | -1.440 | -1.350 | -1.670 | -2.250 | -2.120 | -3.220 | -2.780 | -5.280 | -0.3000 | -0.0200 | -0.0200 | -0.0200 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 5/5/22 | 7/22/22 | 10/28/22 | 2/17/23 | 5/31/23 | 8/29/23 | 11/30/23 | 2/26/24 | 5/16/24 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 153 | 82.1 | 116 | - |
| Net Cash position 1 | 155 | 239 | 295 | 194 | - | - | - | 327 |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.5295 x | -0.4958 x | 0.7955 x | - |
| Free Cash Flow 1 | -150 | -242 | - | -242 | -423 | -43 | 320 | - |
| ROE (net income / shareholders' equity) | -124% | - | - | -40.3% | - | - | 44.3% | 80.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 11.60 | 17.20 | 15.40 | 5.750 | 0.1700 | 0.2600 | 0.6200 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 3.86 | - | 48.5 | 6.79 | 11 | 3 | - |
| Capex / Sales | - | - | - | 84.19% | 2.84% | 3.2% | 0.44% | - |
| Announcement Date | 2/28/20 | 2/26/21 | 2/24/22 | 2/17/23 | 2/26/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.202
SEK
Average target price
0.625
SEK
Spread / Average Target
+209.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -97.98% | 29.73M | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- XBRANE Stock
- Financials Xbrane Biopharma AB
